In vivo, aclidinium bromide has longer duration of action and reduced potential to induce dry mouth, compared with glycopyrrolate

R. Otal, A. Gavalda, J. Llupià, J. Beleta, M. Miralpeix (Barcelona, Spain)

Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Session: Bronchodilator treatment for asthma and COPD
Session type: Thematic Poster Session
Number: 1187
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Otal, A. Gavalda, J. Llupià, J. Beleta, M. Miralpeix (Barcelona, Spain). In vivo, aclidinium bromide has longer duration of action and reduced potential to induce dry mouth, compared with glycopyrrolate. Eur Respir J 2010; 36: Suppl. 54, 1187

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD
Year: 2008


Aclidinium bromide, a novel long-acting anticholinergic, does not affect QT interval in healthy subjects
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II
Year: 2008


Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 356s
Year: 2007

Effect of aclidinium bromide, a novel long-acting anticholinergic, on salivation, colonic motility and faecal output in different animal models
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD
Year: 2008


Low systemic exposure to aclidinium bromide, a novel long-acting anticholinergic, after multiple doses
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008


LAS100977, a novel β2-agonist, has a longer duration of action and a more favourable therapeutic index than salmeterol in anaesthetised dogs
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010


Bronchodilator/bronchoprotective effects of aclidinium bromide, a novel long-acting anticholinergic: a phase I study
Source: Annual Congress 2007 - Mechanisms and new treatments of COPD
Year: 2007


Monitoring of nasal permeability during the treatmrnt of patients with overlap syndrome with combined broncholytic drug (ipratropium bromide + salbutamol)
Source: Eur Respir J 2001; 18: Suppl. 33, 216s
Year: 2001

Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Six months treatment with salmeterol or ipratropium bromide improves effort tolerance and reduces dyspnoea but does not have any effect on lung function in COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 108s
Year: 2002

Compound X – an inhaled β2 agonist with equivalent potency and superior duration of action (DOA)/ therapeutic index (TI) to salmeterol in the anaesthetised dog model of bronchoconstriction
Source: Annual Congress 2008 - Novel treatments for respiratory disease
Year: 2008

Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II
Year: 2008


Different inhalation volumes do not impact on the aerodynamics of aclidinium bromide delivered using the Genuair® inhaler
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010


Salbutamol or ipratropium bromide: does gender and age influence the response to drugs?
Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases
Year: 2021


Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study
Source: Annual Congress 2007 - New drugs for COPD
Year: 2007


Single dose of of tiotropium bromide (18 mcg) produces a similar bronchodilator response as two doses of formoterol fumarate (12 mcg ) over 24 hours in subjects with moderate-to-severe asthma
Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Year: 2010

A comparison of early bronchodilating responses of Salbutamol, Ipratropium bromide, and the combination of Ipratropium bromide-Salbutamol in stable patients with COPD or asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

Effect of patient age on response to nebulised salbutamol or ipratropium bromide
Source: Annual Congress 2012 - Going with the flow: assessment and evaluation of airway function and its role in patient management
Year: 2012

Absolute bioavailability of inhaled aclidinium bromide and safety and tolerability of aclidinium bromide administered intravenously in healthy subjects
Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Year: 2010